LBL 007
Alternative Names: LBL-007; LBL-007 injectionLatest Information Update: 13 Jul 2024
At a glance
- Originator Leads Biolabs
- Developer BeiGene; Leads Biolabs
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer
- Phase I/II Colorectal cancer; Solid tumours
- No development reported Lymphoma; Malignant melanoma
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase Ib/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 20 May 2024 9417329: No updates
- 05 Apr 2024 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China, Puerto Rico (IV) (NCT05609370)